title: Glycosaminoglycans in childhood urinary tract infections.
abstract: It has been suggested that urinary glycosaminoglycans (GAGs) form a natural defense mechanism against urinary tract infections (UTIs). This study investigated whether urinary GAGs play a role in pediatric UTIs, and whether urinary GAG level can be used to differentiate upper UTI from lower UTI. Forty-one children with UTIs (33 girls and eight boys; mean age 5.4+/-3.7 years) and 46 age- and sex-matched healthy children (35 girls and 11 boys; mean age 6.6+/-3.9 years) were included in the study. Urinary GAG levels were measured at the onset of acute infection and after a 10-day course of antibiotic treatment. Group GAG findings were compared, and comparisons were also made with the patients divided according to sex and according to UTI type (upper versus lower). The mean urinary GAG level in the patient group at the onset of acute infection (pretreatment) was significantly higher than the mean level in the control group (132.2+/-104.8 mg/g vs 42.2+/-27.1 mg/g creatinine, respectively; P <0.01). In the patient group, the mean urinary GAG level after antimicrobial therapy was significantly lower than the pretreatment level (75.9+/-52.1 mg/g vs 132.2+/-104.8 mg/g creatinine, respectively; P <0.01). However, the mean post-treatment level was still higher than the mean level in the controls ( P <0.05). There was no significant difference in urinary GAG levels when patients were categorized as upper versus lower UTI ( P >0.05). The study results suggest that GAGs play an important role in the pathogenesis of UTIs in children, and that measurement of urinary GAGs may be a valuable noninvasive method for evaluating UTIs in this patient group. However, this assay cannot be used to differentiate upper UTI from lower UTI in children.
authors.affiliation: Department of Pediatric Nephrology, Baskent University Faculty of Medicine, Adana Teaching and Medical Research Center, Seyhan Hospital, 01140 Adana, Turkey. nurcem@yahoo.com
authors.forename: Nurcan
authors.initials: N
authors.lastname: Cengiz
authors.forename: Esra
authors.initials: E
authors.lastname: Baskin
authors.forename: Ruksan
authors.initials: R
authors.lastname: Anarat
authors.forename: Pinar Isik
authors.initials: PI
authors.lastname: Agras
authors.forename: Selman Vefa
authors.initials: SV
authors.lastname: Yildirim
authors.forename: Filiz
authors.initials: F
authors.lastname: Tiker
authors.forename: Ali
authors.initials: A
authors.lastname: Anarat
authors.forename: Umit
authors.initials: U
authors.lastname: Saatci
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D016022:Case-Control Studies; D002648:Child; D002675:Child, Preschool; D005260:Female; D006025:Glycosaminoglycans / Q000652:urine*; D006801:Humans; D008297:Male; D014552:Urinary Tract Infections / Q000188:drug therapy / Q000652:urine*
chemical_list: D000900:Anti-Bacterial Agents; D006025:Glycosaminoglycans